The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
ZUMA-3 trial update of brexucabtagene autoleucel in adult patients with R/R B-ALL
Featured:
Bijal ShahDuring the 2022 ASCO Annual Meeting, the ALL Hub spoke with Bijal D. Shah, Moffit Cancer Center, Tampa, US. We asked for a ZUMA-3 trial update of brexucabtagene autoleucel in adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).
ZUMA-3 trial update of brexucabtagene autoleucel in adult patients with R/R B-ALL
Shah shares data from the 2-year follow-up of the ZUMA-3 trial, discussing the long-term impact of allogeneic stem cell transplants. Shah outlines promising findings on overall survival for different patient groups and highlights a lack of trend in toxicity data.
Your opinion matters
On average, how many patients with T-cell acute lymphoblastic leukemia do you see in a year?